The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.
 
Kazuto Nakamura
No Relationships to Disclose
 
Akira Yabuno
Honoraria - AstraZeneca; Eisai; Takeda
 
Toyomi Satoh
Consulting or Advisory Role - AstraZeneca/Hong Kong
Speakers' Bureau - ASKA Pharmaceutical; AstraZeneca/Hong Kong; Bayer; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Fuji Pharma; GE Healthcare; Johnson & Johnson; Kyowa Kirin; Merck; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Pfizer; Takeda; Tsumura & Co.
 
Hiroyuki Fujiwara
No Relationships to Disclose
 
Akira Kurosaki
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Takeda
 
Soichi Yamashita
No Relationships to Disclose
 
Toshihiro Misumi
No Relationships to Disclose
 
Shin-ei Noda
No Relationships to Disclose
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; MSD K.K; Roche; Sanofi; Takeda
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical